Aranesp (Darbepoetin Alfa)350.00
Update: 19 nov. 2019
Grade: [A] - Pharmacy
Active substance: Darbepoetin alfa
Generic Name: darbepoetin alfa
Aranesp is the highest quality drug. Exquisite drug for the treatment of anemia in Long-term kidney disease and chemotherapy. This drug is closely alike to the natural constituent (erythropoietin) in your body that precludes anemia.
Aranesp is an artificial form of protein that supports the body in producing red blood cells.
This protein may be abridged if you have kidney failure or if you are using certain medicines. When fewer red blood cells are produced, you may develop a condition called anemia.
Reason behind the usage of Aranesp drug usage:
Aranesp drug is an ES agent listed for treatment of anemia caused by:
• Chronic Kidney Disease in patients on dialysis and patients who are not on dialysis.
• The effects of concomitant myelosuppressive chemotherapy.
Aranesp Usage by Athletes:
Athletes often use blood doping to enhance performance in athletic activities. Blood doping comprises blood transfusions and the management of erythrocytes. This drug is up to the mark for athletes because in this prescription human erythropoietin is assorted with sialic acid essences to mend stability; stimulates erythrocytes by apportioning progenitor cells and distinguishing them in the bone marrow to induce the release of reticulocytes from the bone marrow into the bloodstream to become erythrocytes.
Aranesp is not recommended for use:
Those cancer patients who are getting hormonal mediators and biotic products unless they also get chemotherapy.
Those cancer patients who are getting chemotherapy when the expected outcome is cure.
As a replacement of RBC transfusions in those patients who need instant adjustment of anemia
Prescribed starting medication for Chronic Kidney Disease patients who are receiving dialysis:
0.45 mcg or kg under the skin or into a vein weekly
0.75 mcg or kg under the skin or into a vein every two weeks
Patients with hemodialysis should receive this medicine by injection into a vein.
Prescribed starting medication for Chronic Kidney Disease patients who are not receiving dialysis:
0.45 mcg or kg under the skin or into a vein at four-week interludes
Prescribed starting medication for patients who are receiving chemotherapy:
2.25 mcg or kg into a vein weekly
500 mcg into a vein every three weeks
Declaim the medication guide and patient history provided by pharmacists before the commencement of drug usage and whenever you get a refill. If you have any queries, inquire your doctor or pharmacist. This medicine is given as an injection under the skin or in a vein as prescribed by your doctor. Patients with hemodialysis should receive this medicine by injection into a vein. Do not wobble this medicine or mix it with other medicines or IV solutions.
It’s a clear, colorless solution. This solution is for injection in a pre-filled syringe, pre-filled pen, and vial.
Before use, visually check for specks or discoloration. If any of these is present, do not use fluid.
If you are inoculating this medication under the skin before each dosage, clean the injection site by rubbing alcohol. Change the injection site once to alleviate the lesions under the skin.
Common side effects: hypertension and peripheral edema.
Other side effects: congestive heart failure and hypervolemia.
Call your physician for guidelines if you miss an Aranesp medication.
Aranesp should be stored in the refrigerator at 2 ° to 8 ° C (36 ° to 46 ° F), not in the freezer.
Do not use an Aranesp vial that is frozen.
Do not leave Aranesp in direct sunlight.